Ben Scruggs - Profile and Investment Details

Investor Profile

Ben Scruggs is a Venture Capital, Private Equity Firm, Investor based in Raleigh, North Carolina, United States with a diverse investment portfolio that includes companies such as Standard Bariatrics, Contego Medical, Clearside Biomedical, Vigil Neuroscience, Artizan Biosciences, MATI Energy, SpineAlign MedicalLysosomal Therapeutics, Kymera Therapeutics, Spyryx Biosciences, Bivarus, IMMvention Therapeutix, Inc., AtaCor Medical, Jumo Health, Clinipace, StrideBio, GrayBug, Nusirt, WalletFi, Ribometrix, Tune Therapeutics, Curoverse, Rodin Therapeutics, Medfusion, GeneCentric Diagnostics, Boragen, Myeloid Therapeutics, Trefoil Therapeutics, Empliant, Veralox Therapeutics, G1 Therapeutics, ArtusLabs, Clinverse, Elligo Health Research, Atsena Therapeutics, PhaseBio Pharmaceuticals, HistoSonics, Boston Immune Technologies & Therapeutics, NeuroTronik, Altis Biosystems, Viamet Pharmaceuticals, Coferon, TetraLogic Pharmaceuticals, ORIG3N, 410 Medical, CVRx, Qpex Biopharma, Qvella Corporation, NurseGrid, Sideris Pharmaceuticals, Wildflower Health, Shattuck Labs, . Over time, Ben Scruggs has demonstrated experience in supporting a range of businesses across various sectors.

While it is not publicly confirmed whether Ben Scruggs is currently seeking new investment opportunities, their past investments provide valuable insight into the types of projects and industries that have attracted their attention.

Startups and entrepreneurs operating in sectors related to Health Care, Regenerative Medicine, Wellness, Women Founded, Healthcare Innovation, Life Science, Medical Technologies, Information Technology (IT), Biotechnology, Healthcare IT, Medical Devices, Drug Development, Electronic Health Records (EHR), Health and Hospital Services, Precision Medicine, Clinical Trials, Gene Therapy, Personalized Medicine, Medical Diagnostics, Health Diagnostics, Digital Health, Medical, B2B, Therapeutics, Pharmaceuticals may find it worthwhile to explore potential connections with Ben Scruggs, as their portfolio suggests a familiarity and interest in this area.

Understanding Ben Scruggs’s investment history can offer useful context for founders considering outreach and help identify whether there is a potential fit based on strategic alignment and market focus.